Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, which is majority-owned by Alvogen, has been under the leadership and guidance of Lin since 2016. Lin will continue to support Lotus as a director of the board.
Wessman’s current role at Alvogen will remain unchanged as he pursues continued growth with Lotus, which is poised to become a leading developer and supplier of oncology products globally.
Commenting on his new role, Wessman said:
"Since 2013, when Alvogen became a leading shareholder at Lotus, the company has gone from strength to strength. We have not only multiplied Lotus’ revenues and enhanced our profitability, but we’ve enabled Lotus’ transformation from a local player to a regional APAC pharmaceutical company.
“We are now entering the second phase in the development of Lotus. Through a well-targeted pipeline of oncology products, Lotus is well positioned to continue its growth, not only in Taiwan and the APAC region, but around the world, to become a global leader in the field of oncology. The synergistic relationship between Lotus and Alvogen provides Lotus with the geographical reach necessary to maximize the value from its research and development programs.”
Lotus is a pharmaceutical company headquartered in Taiwan, primarily focusing on addressing the fast-growing oncology market and exclusive marketing of biosimilars in the APAC region. The company boasts a best in class R&D and manufacturing platform in both Taiwan and Korea. Its partnership with Alvogen, along with alliances with other top-tier pharma companies, allows Lotus to reach worldwide markets.